Synergy Pharmaceuticals Announces Approval of Merger With Callisto Pharmaceuticals and Other Actions at Annual Meeting of Stockholders
January 15, 2013 05:00 ET
|
Synergy Pharmaceuticals
NEW YORK, Jan. 15, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP) ("Synergy") today announced that it convened its annual meeting of stockholders yesterday and it has received the...
Synergy Announces Adjournment of Annual Meeting
January 03, 2013 16:30 ET
|
Synergy Pharmaceuticals
NEW YORK, Jan. 3, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP) today announced that it convened its annual meeting of stockholders on Thursday, January 3, 2013 and adjourned...
Synergy Announces Positive Results From Plecanatide Phase IIb/III Trial in Patients With Chronic Idiopathic Constipation
January 02, 2013 05:00 ET
|
Synergy Pharmaceuticals
Topline Data Show That Plecanatide Met Primary and Key Secondary Endpoints
NEW YORK, Jan. 2, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP) today announced that plecanatide,...
Synergy Pharmaceuticals Completes Phase I Trial of SP-333, a Second-Generation GC-C Agonist to Treat Gastrointestinal Diseases
December 28, 2012 05:00 ET
|
Synergy Pharmaceuticals
NEW YORK, Dec. 28, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, announced today the successful...
Synergy Pharmaceuticals Begins Phase IIb Trial of Plecanatide in Irritable Bowel Syndrome With Constipation (IBS-C)
December 27, 2012 05:00 ET
|
Synergy Pharmaceuticals
NEW YORK, Dec. 27, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, announced today that dosing has...
Synergy Pharmaceuticals Presents Poster on Novel Mechanism of Action of SP-333, an Agonist of Guanylate Cyclase-C for Treatment of Ulcerative Colitis
December 14, 2012 08:00 ET
|
Synergy Pharmaceuticals
NEW YORK, Dec. 14, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today announced that a poster...
Synergy Pharmaceuticals to Present at Piper Jaffray Healthcare Conference
November 21, 2012 08:50 ET
|
Synergy Pharmaceuticals
NEW YORK, Nov. 21, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today announced that its President...
Synergy Pharmaceuticals Reports Third Quarter 2012 Financial Results
November 13, 2012 16:31 ET
|
Synergy Pharmaceuticals
NEW YORK, Nov. 13, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today reported its financial results...
Synergy Pharmaceuticals Announces Extension for Filing of Third Quarter Form 10-Q Due to Hurricane Sandy
November 09, 2012 17:00 ET
|
Synergy Pharmaceuticals
NEW YORK, Nov. 9, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, announced today that, in accordance...
Synergy Pharmaceuticals Highlights Mechanistic Features of Plecanatide, a Novel Investigational Drug for Chronic Idiopathic Constipation
October 22, 2012 17:00 ET
|
Synergy Pharmaceuticals
NEW YORK, Oct. 22, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today announced the preclinical...